In case you missed it: April 5 to April 9
It was a very busy week for the Contemporary OB/GYN® team.
This week’s top articles included:
Hormone therapy for postmenopausal women with nocturia
A prospective observational study found that hormone therapy resulted in a significant reduction in nocturia prevalence and bother in postmenopausal women with two nocturnal voids.
Oral contraceptive and ovarian function
A prospective study to assess the effects of an oral contraceptive containing estetrol and drospirenone on ovarian function found treatment achieved complete ovulation inhibition.
Current Management of Uterine Fibroids
Two experts discuss the goals of treatment and the expanding therapeutic landscape. This article was sponsored by Myovant Sciences.
Reduced Testing, Higher Positivity Rates for Prescription and Illegal Drugs During the COVID-19 Pandemic in 2020
Lower levels of testing and higher positivity rates, higher rates of dangerous drug combination use, and increases in fatal and non-fatal overdoses during the coronavirus disease 2019 (COVID-19) pandemic reveal a need for more resources to address the opioid epidemic in the United States.
Evaluation & Management of COVID-19 in Pregnancy
Treating COVID-19 in pregnant patients brings extra challenges, risks.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
